Mizuho Raises Price Target for BioXcel Therapeutics to $4.00, Maintains Neutral Rating.

Mizuho analyst Graig Suvannavejh raised the price target for BioXcel Therapeutics (BTAI) from $2.00 to $4.00, a 100% increase, while maintaining a Neutral rating. This update comes amidst historical ratings from other analysts, including HC Wainwright & Co.'s Buy rating with a $10.00 price target. The average brokerage recommendation is 2.5, indicating an "Outperform" status. The estimated GF Value for BTAI in one year is $14.61, suggesting a 332.25% upside from the current price.

Mizuho analyst Graig Suvannavejh recently raised the price target for BioXcel Therapeutics (BTAI) from $2.00 to $4.00, a 100% increase, while maintaining a Neutral rating. This update comes amidst historical ratings from other analysts, including HC Wainwright & Co.'s Buy rating with a $10.00 price target. The average brokerage recommendation is 2.5, indicating an "Outperform" status. The estimated GF Value for BTAI in one year is $14.61, suggesting a 332.25% upside from the current price.

The positive outlook on BTAI's stock is driven by recent clinical trial results. BioXcel Therapeutics announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial. The trial demonstrated that BXCL501, a sublingual film formulation of dexmedetomidine, showed significant reductions in agitation symptoms compared to placebo across various severities and durations of treatment. The trial was not powered for efficacy assessments, but the data further support the potential of BXCL501 for use in the outpatient setting.

BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of IGALMI® in the outpatient setting. The company is hosting a virtual KOL call with Dr. Leslie Citrome on the SERENITY At-Home program at 2 p.m. today, providing further insights into the trial's findings.

The market for at-home agitation treatment is substantial, with no FDA-approved options currently available. The SERENITY At-Home trial results open the door for patients and their caregivers to better manage agitation outside of the emergency department, reducing burden on families and the healthcare system.